Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
PHASE3
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 m...
Status
Completed
Location
205.419.01058 Boehringer Ingelheim Investigational Site
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
PHASE2
The primary objective of this study is to determine the optimum dose(s) of ...
Status
Completed
Location
1237.9.00152 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
PHASE2
The primary objective of this trial is to evaluate the safety and efficacy ...
Status
Completed
Location
205.443.12003 Boehringer Ingelheim Investigational Site
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
PHASE3
The objective of the trial is to compare the lung function profile of once ...
Status
Completed
Location
1237.11.32002 Boehringer Ingelheim Investigational Site
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
PHASE3
The study is intended to characterize the lung function profile of BI1744 i...
Status
Completed
Location
1222.39.32003 Boehringer Ingelheim Investigational Site